Featured Stories

Dr. Harriet Kluger helped Bill participate in a clinical trial with ipilimumab in combination with an anti-PD1 drug, Nivolumab to treat his stage III melanoma. 

Due to the severity of Dina's diagnosis, Dr. Mario Sznol suggested she join a clinical trial that offered a combined immunotherapy, which at the time was a very new therapy.

Mr. Metz’s journey illustrates the incredible strides that have been made in treating melanoma, a cancer that just ten years ago had a much more frightening prognosis. 

Researchers at Yale discovered that sun damage continues even when we’re out of the sun and that melanin, the pigment that gives skin its color, may be both protective and harmful.

In a Phase I trial, a new combination of drugs proved highly effective against an especially dangerous cancer: melanoma.